Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
JM Prins, S Jurriaans, RME van Praag, H Blaak… - Aids, 1999 - journals.lww.com
JM Prins, S Jurriaans, RME van Praag, H Blaak, R van Rij, PTA Schellekens, IJM Ten Berge…
Aids, 1999•journals.lww.comBackground: A stable reservoir of latently infected, resting CD4 T cells has been
demonstrated in HIV-1-infected patients despite prolonged antiretroviral treatment. This is a
major barrier for the eradication of HIV by antiretroviral agents alone. Activation of these
cells in the presence of antiretroviral therapy might be a strategy to increase the turnover
rate of this reservoir. Methods: Three HIV-1-positive patients on potent antiretroviral therapy,
in whom plasma viremia had been suppressed to below 5 copies/ml for at least 26 weeks …
demonstrated in HIV-1-infected patients despite prolonged antiretroviral treatment. This is a
major barrier for the eradication of HIV by antiretroviral agents alone. Activation of these
cells in the presence of antiretroviral therapy might be a strategy to increase the turnover
rate of this reservoir. Methods: Three HIV-1-positive patients on potent antiretroviral therapy,
in whom plasma viremia had been suppressed to below 5 copies/ml for at least 26 weeks …
Abstract
Background:
A stable reservoir of latently infected, resting CD4 T cells has been demonstrated in HIV-1-infected patients despite prolonged antiretroviral treatment. This is a major barrier for the eradication of HIV by antiretroviral agents alone. Activation of these cells in the presence of antiretroviral therapy might be a strategy to increase the turnover rate of this reservoir.
Methods:
Three HIV-1-positive patients on potent antiretroviral therapy, in whom plasma viremia had been suppressed to below 5 copies/ml for at least 26 weeks, were treated with a combination of OKT3 (days 1-5) and recombinant human IL-2 (days 2-6).
Results:
The side-effects were fever, headache, nausea, diarrhea, and in one of the patients transient renal failure and seizures. The regimen resulted in profound T cell activation. In one patient plasma HIV-1 RNA transiently increased with a peak at 1500 copies/ml. In the other two patients plasma HIV-1 RNA levels remained below the detection limit, but HIV-1 RNA levels in the lymph nodes increased two-to threefold. All patients developed antibodies against OKT3.
Conclusion:
OKT3/IL-2 resulted in T cell activation and proliferation, and could stimulate HIV replication in patients having achieved prolonged suppression of plasma viremia. OKT3/IL-2 therapy was toxic and rapidly induced antibodies against OKT3.
Lippincott Williams & Wilkins